PLX4032, a selective BRAFV600Ekinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWTmelanoma cells

BRAFV600EKis a frequent mutationally active tumor-specific kinase in melanomas that is currently targeted for therapy by the specific inhibitor PLX4032. Our studies with melanoma tumor cells that are BRAFV600EKand BRAFWTshowed that, paradoxically, while PLX4032 inhibited ERK12 in the highly sensitive BRAFV600EK, it activated the pathway in the resistant BRAFWTcells, via RAF1 activation, regardless of the status of mutations in NRAS or PTEN. The persistently active ERK12 triggered downstream effectors in BRAFWTmelanoma cells and induced changes in the expression of a wide-spectrum of genes associated with cell cycle control. Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions. The results suggest that the drug can confer an advantage to BRAFWTprimary and metastatic tumor cells in vivo and provide markers for monitoring clinical responses.